Under the directive issued by the Ministry of Health, localities’ health departments, hospitals under the ministry and drug manufacturers, exporters and importers need to take measures to prevent shortages of medicines and raw materials amid disruptions to international transport and trade.
The Drug Administration urged units to urgently review stockpiles of medicines and raw materials, assess supplier capacity and develop appropriate reserve plans, prioritising essential drugs for emergency care and treatment to ensure stable supply.
Pharmaceutical companies were ordered to proactively plan production, imports and raw material reserves, and prepare contingency measures in case of market or supply chain fluctuations amid the Middle East tensions.
Local health authorities were also instructed to closely monitor drug availability, promptly report any difficulties and propose solutions.
The Drug Administration said any risks of shortages or supply disruptions must be reported in detail to enable timely action by the ministry.